Crescita Therapeutics Inc (CTX) — Cash Flow-to-Debt Ratio
Crescita Therapeutics Inc (CTX) has a Cash Flow-to-Debt Ratio of 0.09x as of December 2025, meaning its operating cash flow of CA$416.00K could theoretically repay 0% of its total liabilities (CA$4.75 Million) in one year. See CTX free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Crescita Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Crescita Therapeutics Inc across 12 annual periods. Also explore CTX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Crescita Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Crescita Therapeutics Inc. For market capitalisation and broader financial context, see CTX market cap.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | CA$1.07 Million | CA$4.75 Million | ▼ -50.7% |
| 2024 | 0.46x | CA$2.73 Million | CA$5.95 Million | ▲ +27.5% |
| 2023 | 0.36x | CA$2.08 Million | CA$5.78 Million | ▲ +360.3% |
| 2022 | -0.14x | CA$-1.02 Million | CA$7.39 Million | ▲ +27.4% |
| 2021 | -0.19x | CA$-1.60 Million | CA$8.40 Million | ▼ -119.3% |
| 2020 | 0.98x | CA$5.61 Million | CA$5.70 Million | ▲ +6.3% |
| 2019 | 0.93x | CA$5.31 Million | CA$5.73 Million | ▲ +636.3% |
| 2018 | -0.17x | CA$-1.48 Million | CA$8.56 Million | ▲ +77.9% |
| 2017 | -0.78x | CA$-7.40 Million | CA$9.46 Million | ▲ +31.7% |
| 2016 | -1.15x | CA$-18.58 Million | CA$16.21 Million | ▲ +62.5% |
| 2015 | -3.06x | CA$-13.92 Million | CA$4.55 Million | ▼ -22.8% |
| 2014 | -2.49x | CA$-9.30 Million | CA$3.74 Million | — |